X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6739) 6739
Publication (451) 451
Book Review (41) 41
Book Chapter (16) 16
Magazine Article (10) 10
Dissertation (6) 6
Conference Proceeding (5) 5
Newspaper Article (2) 2
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4307) 4307
male (3552) 3552
benzimidazoles - administration & dosage (3064) 3064
animals (2873) 2873
index medicus (2868) 2868
female (2612) 2612
benzimidazoles - therapeutic use (2303) 2303
benzimidazoles - pharmacology (1970) 1970
middle aged (1557) 1557
adult (1332) 1332
rats (1227) 1227
aged (1225) 1225
pharmacology & pharmacy (1217) 1217
benzimidazoles - adverse effects (1154) 1154
administration, oral (1132) 1132
dabigatran (970) 970
treatment outcome (967) 967
dose-response relationship, drug (811) 811
mice (737) 737
benzimidazoles - pharmacokinetics (714) 714
beta-alanine - analogs & derivatives (688) 688
hypertension - drug therapy (643) 643
drug therapy, combination (634) 634
blood pressure - drug effects (621) 621
hypertension (566) 566
peripheral vascular disease (555) 555
time factors (506) 506
double-blind method (504) 504
2-pyridinylmethylsulfinylbenzimidazoles (489) 489
drug therapy (476) 476
pharmacokinetics (427) 427
anticoagulants - administration & dosage (426) 426
drug administration schedule (410) 410
omeprazole - analogs & derivatives (406) 406
rivaroxaban (404) 404
oncology (397) 397
telmisartan (388) 388
tetrazoles - administration & dosage (384) 384
warfarin (382) 382
anticoagulants - therapeutic use (379) 379
tetrazoles - pharmacology (377) 377
benzoates - administration & dosage (374) 374
research (372) 372
cardiac & cardiovascular systems (368) 368
antihypertensive agents - administration & dosage (359) 359
aged, 80 and over (353) 353
rats, sprague-dawley (353) 353
beta-alanine - administration & dosage (350) 350
dosage and administration (349) 349
angiotensin ii type 1 receptor blockers - administration & dosage (348) 348
atrial fibrillation - drug therapy (346) 346
prevention (340) 340
benzimidazoles (335) 335
efficacy (335) 335
medicine, general & internal (333) 333
adolescent (327) 327
analysis (323) 323
stroke - prevention & control (323) 323
gastroenterology & hepatology (318) 318
risk factors (318) 318
anticoagulants - adverse effects (316) 316
abridged index medicus (313) 313
angiotensin ii type 1 receptor blockers - therapeutic use (313) 313
omeprazole (309) 309
tetrazoles - therapeutic use (307) 307
benzoates - therapeutic use (306) 306
therapy (306) 306
antihypertensive agents - therapeutic use (304) 304
beta-alanine - therapeutic use (304) 304
angiotensin ii type 1 receptor blockers - pharmacology (303) 303
anticoagulants (302) 302
beta-alanine - adverse effects (297) 297
candesartan (287) 287
disease models, animal (286) 286
health aspects (285) 285
angiotensin receptor antagonists (283) 283
anthelmintics - administration & dosage (280) 280
anthelmintics - therapeutic use (278) 278
proton pump inhibitors (276) 276
sheep (276) 276
care and treatment (273) 273
drug interactions (273) 273
rats, wistar (273) 273
atrial fibrillation (269) 269
hypertension - physiopathology (268) 268
stroke (267) 267
medicine & public health (264) 264
benzimidazoles - blood (260) 260
dabigatran etexilate (255) 255
angiotensin (250) 250
benzimidazoles - chemistry (249) 249
morpholines - therapeutic use (249) 249
double-blind (248) 248
expression (248) 248
cancer (245) 245
veterinary sciences (241) 241
clinical trials as topic (238) 238
blood-pressure (237) 237
prospective studies (235) 235
benzoates - pharmacology (234) 234
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6138) 6138
Russian (165) 165
German (147) 147
Japanese (68) 68
French (58) 58
Spanish (48) 48
Chinese (23) 23
Polish (16) 16
Czech (15) 15
Italian (15) 15
Dutch (13) 13
Portuguese (13) 13
Hungarian (10) 10
Swedish (7) 7
Turkish (5) 5
Ukrainian (5) 5
Danish (4) 4
Norwegian (4) 4
Slovak (3) 3
Bulgarian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Croatian (1) 1
Finnish (1) 1
Korean (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2014, Volume 64, Issue 11, pp. 1128 - 1139
Abstract Background Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | monitoring | laboratory | apixaban | MEASURING RIVAROXABAN | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | DABIGATRAN CONCENTRATIONS | PROTHROMBIN TIME | PARTIAL THROMBOPLASTIN TIME | COAGULATION ASSAYS | IN-VITRO | FACTOR-XA INHIBITOR | PLASMA-CONCENTRATIONS | INTERNATIONAL NORMALIZED RATIO | Anticoagulants - administration & dosage | Humans | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Factor Xa Inhibitors - administration & dosage | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - pharmacology | Factor Xa Inhibitors - pharmacology | beta-Alanine - analogs & derivatives | Pyrazoles - pharmacology | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Pyrazoles - administration & dosage | Partial Thromboplastin Time | Anticoagulants - pharmacology | Benzimidazoles - pharmacology | Drug Monitoring | Pyridones - pharmacology | Measurement | Anticoagulants (Medicine) | Vitamins | Studies | Anticoagulants | Plasma | Bibliographic literature | Laboratories | Drug therapy | Drug dosages | Bone surgery
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 3, pp. 457 - 471.e5
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 03/2014, Volume 12, Issue 3, pp. 320 - 328
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 05/2015, Volume 45, Issue 5, pp. 408 - 410
Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent... 
Chemo-gynecology | Molecular Dx | Gynecol-med | PEGYLATED LIPOSOMAL DOXORUBICIN | CARBOPLATIN | gynecol-med | BEVACIZUMAB | molecular Dx | COMBINATION | CHEMOTHERAPY | PACLITAXEL | PHASE-III TRIAL | THERAPY | ONCOLOGY | DOUBLE-BLIND | PROGRESSION | chemo-gynecology | Piperazines - administration & dosage | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Folic Acid - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Vinca Alkaloids - administration & dosage | Benzimidazoles - administration & dosage | Doxorubicin - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Antimetabolites, Antineoplastic - pharmacology | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Everolimus | Ovarian Neoplasms - drug therapy | Recombinant Fusion Proteins - administration & dosage | Doxorubicin - administration & dosage | Sirolimus - analogs & derivatives | Folic Acid - analogs & derivatives | Phthalazines - administration & dosage | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Angiogenesis Inhibitors - pharmacology | Carboplatin - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors | Polyethylene Glycols - administration & dosage | Sirolimus - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Nivolumab | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Topotecan - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage
Journal Article
European Heart Journal, ISSN 0195-668X, 02/2013, Volume 34, Issue 7, pp. 489 - 500
Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently available for prevention of venous... 
Novel oral anticoagulants | Bleeding | Management | RECOMBINANT FACTOR-VIIA | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | RANDOMIZED EVALUATION | INTRACRANIAL HEMORRHAGE | ACTIVATED FACTOR-VII | FACTOR-XA INHIBITOR | DABIGATRAN ETEXILATE | VENOUS THROMBOEMBOLISM | PROTHROMBIN COMPLEX CONCENTRATE | NONVALVULAR ATRIAL-FIBRILLATION | Plasma | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Antithrombins - administration & dosage | Hemorrhage - prevention & control | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | beta-Alanine - pharmacology | Renal Insufficiency - complications | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Acute Disease | beta-Alanine - adverse effects | Administration, Oral | Morpholines - administration & dosage | Risk Factors | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Anticoagulants - pharmacology | Antithrombins - adverse effects | Blood Coagulation Tests | Benzimidazoles - pharmacology | Aged | Hemostatics - therapeutic use | Pyridones - adverse effects | Pyridones - pharmacology | Renal Dialysis
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Graphical abstract 
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | PLUS RIBAVIRIN | VIRUS-INFECTION | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | Chronic | HEPATOCELLULAR-CARCINOMA | TREATMENT-EXPERIENCED PATIENTS | Hepatitis C | GASTROENTEROLOGY & HEPATOLOGY | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2017, Volume 64, Issue 12, pp. 1711 - 1720
Background. Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes. We examined the... 
real-world | HCV | HIV | DAA | INFECTIOUS DISEASES | HIV/HCV | LEDIPASVIR-SOFOSBUVIR | CHRONIC HEPATITIS-C | MICROBIOLOGY | COINFECTED INDIVIDUALS | IMMUNOLOGY | INFECTION | COHORT | Uridine Monophosphate - administration & dosage | Anilides - therapeutic use | Hepatitis C - drug therapy | Coinfection - drug therapy | Veterans | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Practice Patterns, Physicians | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Female | Fluorenes - administration & dosage | Hepatitis C - complications | Registries | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Administration, Oral | Antiviral Agents - therapeutic use | HIV Infections - virology | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Antiviral Agents - administration & dosage | Coinfection - virology | Macrocyclic Compounds - therapeutic use | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | Hepatitis C - virology | HIV Infections - drug therapy | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Cohort Studies | Antiviral agents | Care and treatment | Dosage and administration | Hepatitis C | HIV infection
Journal Article
Stroke, ISSN 0039-2499, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). Health technology assessment agencies... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | ENOXAPARIN | meta-analysis | RANDOMIZED-TRIAL | REPLACEMENT | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | THROMBOSIS PROPHYLAXIS | US HOSPITALS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | UNFRACTIONATED HEPARIN | REGISTRY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article